Details

Graham Lumsden, chief executive of Motif Bio (LON:MTFB), tells Proactive Investors he is confident about the path forward for Iclaprim. After a ‘collaborative meeting’ with the FDA, the American regulator gave the biopharmaceutical company the green light to begin phase 111 clinical trials on its next-generation antibiotic.

Lumsden is now putting together a strategic business development plan looking at appropriate partners for one or both of the clinical trials to bring in upfront payments and satisfy funding requirements for the trials.